2 C
New York
Wednesday, February 1, 2023

Pieris Pharmaceuticals Inc. (NASDAQ: PIRS): Is It A Buying Opportunity Again?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Pieris Pharmaceuticals Inc. (PIRS) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.01, or -0.71%, to $1.40. The Pieris Pharmaceuticals Inc. has recorded 1,209 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346).


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Stocks Info

PIRS belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $1.41 and fluctuated between $1.4200 as its day high and $1.3000 as its day low. The current market capitalization of Pieris Pharmaceuticals Inc. is $94.86M. A total of 0.65 million shares were traded on the day, compared to an average of 320.27K shares.

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, PIRS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 1 BUYs and 0 SELLs from insiders. Insiders purchased 6,000 shares during that period but sold 0.

In the most recent transaction, Demuth Tim bought 6,000 shares of PIRS for 1.71 per share on May 13. After the transaction, the Chief Medical Officer now owns 6,000 company shares.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for PIRS in the last 3 months, the mean price target is $7.00 with high estimates of $7.00 and low estimates of $7.00. In terms of 52-week highs and lows, PIRS has a high of $3.75 and a low of $0.85.

As of this writing, PIRS has an earnings estimate of -$0.16 per share for the current quarter. EPS was calculated based on a consensus of 2 estimates, with a high estimate of -$0.13 per share and a lower estimate of -$0.19. The company reported an EPS of -$0.07 in the last quarter, which was 36.40% higher than expectations of -$0.11.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 1 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PIRS is Buy with a score of 5.00. A total of 1 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles